Ovid Therapeutics Inc. (OVID)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
0.73
-0.00 (-0.25%)
At close: Jan 28, 2025, 1:51 PM
Income Statement (Annual)
Get detailed income statement breakdowns, uncovering revenue, expenses, and much more.
Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
Revenue | 391.69K | 1.50M | 208.38M | 12.62M | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 1.38M | n/a | n/a | 255.00K | 141.73K | 80.31K | 56.51K | 11.78K | n/a |
Gross Profit | 391.69K | 121.14K | 208.38M | 12.62M | -255.00K | -141.73K | -80.31K | -56.51K | -11.78K | n/a |
Operating Income | -59.28M | -55.55M | 124.21M | -81.43M | -61.41M | -52.93M | -65.01M | -22.54M | -13.19M | -446.89K |
Interest Income | 4.90M | n/a | n/a | 395.40K | 948.22K | 952.07K | 201.51K | n/a | 30.28K | n/a |
Pretax Income | -52.34M | -54.17M | 124.16M | -81.04M | -60.46M | -51.98M | -64.81M | -22.41M | -13.16M | -446.89K |
Net Income | -52.34M | -51.41M | 122.83M | -80.73M | -59.26M | -51.98M | -64.81M | -22.41M | -13.16M | -446.89K |
Selling & General & Admin | 31.09M | 32.43M | 37.23M | 30.63M | 19.25M | 19.14M | 15.04M | 12.95M | 6.58M | 341.52K |
Research & Development | 28.59M | 24.62M | 46.94M | 63.42M | 42.16M | 33.79M | 49.97M | 9.59M | 6.61M | 105.38K |
Other Expenses | 1.00 | 1.38M | -45.69K | 395.40K | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 59.67M | 57.05M | 84.17M | 94.05M | 61.41M | 52.93M | 65.01M | 22.54M | 13.19M | 446.89K |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 59.67M | 57.05M | 84.17M | 94.05M | 61.41M | 52.93M | 65.01M | 22.54M | 13.19M | 446.89K |
Income Tax | n/a | -2.76M | 1.33M | -306.85K | -1.20M | 951.73K | -80.31K | -950 | n/a | n/a |
Shares Outstanding (Basic) | 70.58M | 70.42M | 67.48M | 58.45M | 39.22M | 24.63M | 19.34M | 19.60M | 19.60M | 4.75M |
Shares Outstanding (Diluted) | 70.58M | 70.42M | 68.07M | 58.45M | 39.22M | 24.63M | 19.34M | 19.60M | 19.60M | 4.75M |
EPS (Basic) | -0.74 | -0.73 | 1.78 | -1.38 | -1.51 | -2.11 | -3.35 | -1.14 | -0.67 | -0.09 |
EPS (Diluted) | -0.74 | -0.73 | 1.78 | -1.38 | -1.51 | -2.11 | -3.35 | -1.14 | -0.67 | -0.09 |
EBITDA | -57.69M | -52.79M | 124.40M | -81.12M | -60.21M | -52.79M | -64.73M | -22.48M | -13.18M | -444.58K |
Depreciation & Amortization | 1.60M | 1.38M | 237.00K | 307.00K | 255.00K | 141.73K | 80.31K | 56.51K | 11.78K | 2.31K |